Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/80335
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYoung, Barnabyen
dc.contributor.authorSadarangani, Sapnaen
dc.contributor.authorYew, Haur Senen
dc.contributor.authorYung, Chee Fuen
dc.contributor.authorLeo, Yee Sinen
dc.contributor.authorChen, Mark I-Chengen
dc.contributor.authorWilder-Smith, Anneliesen
dc.date.accessioned2017-03-01T06:39:54Zen
dc.date.accessioned2019-12-06T13:47:26Z-
dc.date.available2017-03-01T06:39:54Zen
dc.date.available2019-12-06T13:47:26Z-
dc.date.issued2017en
dc.identifier.citationYoung, B., Sadarangani, S., Yew, H. S., Yung, C. F., Leo, Y. S., Chen, M. I.-C., et al. (2017). The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial. Trials, 18(67).en
dc.identifier.issn1745-6215en
dc.identifier.urihttps://hdl.handle.net/10356/80335-
dc.identifier.urihttp://hdl.handle.net/10220/42142en
dc.description.abstractBackground: The seasonal influenza vaccine is less effective in older people and a single dose is unlikely to provide the year-round protection necessary for tropical climates which have year-round influenza virus activity. This study aims to assess the effect of a trivalent inactivated influenza vaccine (IIV3) booster at 180 days on haemagglutination-inhibition (HI) antibody titres for each of the influenza strains present in the administered vaccine in older people aged 65 years or above in Singapore. Methods/design: This is a single-centre, randomised, observer-blind, active-comparator controlled, parallel-group, phase IV trial in 200 adults aged 65 years or older. Study participants will be assigned to one of two groups in a 1:1 ratio and followed for 1 year, with five scheduled visits. The control group will receive IIV3 at day 1, and an active comparator (Tetanus-diphtheria-pertussis vaccine) at day 180. Participants in the experimental group will receive IIV3 containing the same strains at day 1 and day 180. Endpoints are immunological, and include measures of HI titres, microneutralisation titres (MN) and cell-mediated immunity from first vaccination up to day 360. Discussion: If superiority of 6-monthly influenza vaccination is demonstrated, this study could form the basis for a larger clinical trial with influenza infection as the primary endpoint. Trial registration: ClinicalTrials.gov, ID: NCT02655874. Registered on 12 January 2016.en
dc.format.extent9 p.en
dc.language.isoenen
dc.relation.ispartofseriesTrialsen
dc.rights© 2017 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectInfluenzaen
dc.subjectVaccineen
dc.titleThe immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trialen
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en
dc.identifier.doi10.1186/s13063-017-1808-8en
dc.description.versionPublished versionen
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
The immune response to 6-monthly versus annual standard dose.pdf678.73 kBAdobe PDFThumbnail
View/Open

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.